Tags

Type your tag names separated by a space and hit enter

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
Clin Infect Dis 2016; 63(12):1615-1618CI

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

Authors+Show Affiliations

Department of Medicine. Antibiotic Management Program. XDR Pathogen Laboratory, University of Pittsburgh Medical Center.Department of Medicine. Department of Pharmacy and Therapeutics, University of Pittsburgh. Antibiotic Management Program.Department of Medicine.XDR Pathogen Laboratory, University of Pittsburgh Medical Center.Department of Medicine.Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark.Department of Medicine.Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark.Department of Medicine. XDR Pathogen Laboratory, University of Pittsburgh Medical Center. VA Pittsburgh Healthcare System, Pennsylvania.Department of Medicine. Antibiotic Management Program. XDR Pathogen Laboratory, University of Pittsburgh Medical Center.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27624958

Citation

Shields, Ryan K., et al. "Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 63, no. 12, 2016, pp. 1615-1618.
Shields RK, Potoski BA, Haidar G, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin Infect Dis. 2016;63(12):1615-1618.
Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., ... Nguyen, M. H. (2016). Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 63(12), pp. 1615-1618.
Shields RK, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. PubMed PMID: 27624958.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. AU - Shields,Ryan K, AU - Potoski,Brian A, AU - Haidar,Ghady, AU - Hao,Binghua, AU - Doi,Yohei, AU - Chen,Liang, AU - Press,Ellen G, AU - Kreiswirth,Barry N, AU - Clancy,Cornelius J, AU - Nguyen,M Hong, Y1 - 2016/09/13/ PY - 2016/05/17/received PY - 2016/08/14/accepted PY - 2016/9/15/pubmed PY - 2017/12/1/medline PY - 2016/9/15/entrez KW - Klebsiella pneumoniae carbapenemase KW - carbapenem-resistant Enterobacteriaceae KW - ceftazidime-avibactam resistance SP - 1615 EP - 1618 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin. Infect. Dis. VL - 63 IS - 12 N2 - Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/27624958/Clinical_Outcomes_Drug_Toxicity_and_Emergence_of_Ceftazidime_Avibactam_Resistance_Among_Patients_Treated_for_Carbapenem_Resistant_Enterobacteriaceae_Infections_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciw636 DB - PRIME DP - Unbound Medicine ER -